

## IL-6 Monoclonal Antibody

catalog number: **AN200102P**

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Reactivity</b>	Human
<b>Immunogen</b>	Recombinant Human IL-6 Protein
<b>Host</b>	Mouse
<b>Isotype</b>	IgG1
<b>Clone</b>	4D11
<b>Purification</b>	Protein A
<b>Buffer</b>	0.2 µm filtered solution in PBS


### Applications

Applications	Recommended Dilution
<b>WB</b>	1:500-1:2000
<b>IHC-P</b>	1:30-1:100


### Data



Immunohistochemistry of paraffin-embedded human spleen using IL-6 Monoclonal Antibody at dilution of 1:60.



Immunohistochemistry of paraffin-embedded human liver using IL-6 Monoclonal Antibody at dilution of 1:60.



Western Blot with IL-6 Monoclonal Antibody at dilution of 1:500. Lane A: A549 Whole Cell Lysate, Lane B: HeLa Whole Cell Lysate, Lane C: HepG2 Whole Cell Lysate, Lysates/proteins at 30 µg per lane.

**Observed-MW:30 kDa**

**Calculated-MW:24 kDa**

### Preparation & Storage

<b>Storage</b>	This antibody can be stored at 2°C-8°C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20°C to -80°C. Preservative-Free. Avoid repeated freeze-thaw cycles.
<b>Shipping</b>	Ice bag

### Background

### For Research Use Only

Interleukin-6 (IL-6) is a pleiotropic, alpha-helical, phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. Mature human IL-6 is 183 amino acids (aa) in length expressed as a 22-28 kDA molecular weight protein. IL-6 shares 39% aa sequence identity with mouse and rat IL-6. Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization. gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor. IL-6, along with TNF-alpha and IL-1, function to drive the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis. IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise. In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells.